Dermatology Times

APRIL 12, 2024

Dr Linda Stein-Gold and Dr Michael Cameron assess the safety and tolerability of topical ruxolitinib cream, offering guidance on counseling patients about the black box warning. They also address the perception of limited treatment access and strategies for overcoming this barrier.

Safety 36

Safety Treatments 36

Dermatology Times

MARCH 28, 2024

Mark Lebwohl, MD, and Saakshi Khattri, MD, examine the use of spesolimab in various diseases, including generalized pustular psoriasis (GPP), and comment on the use and safety of deucravacitinib.

Safety 36

Safety 36

Dermatology Times

MARCH 18, 2024

Henry Lim, MD, shares insights on JAK inhibitor safety and the poster presented at the AAD Annual Meeting

Safety 70

Safety 70

Online Laser Training

AUGUST 13, 2020

version of our Laser and Intense Pulsed Light Physics and Safety Core of Knowledge course has been awarded 1 Board of Laser Safety (BLS) Certification Maintenance (CM) point. continent, and makes our Laser and Intense Pulsed Light Physics and Safety Core of Knowledge course one of the most recognised globally.

Safety 78

Safety Training Education 78

Online Laser Training

AUGUST 13, 2020

version of our Laser and Intense Pulsed Light Physics and Safety Core of Knowledge course has been awarded 1 Board of Laser Safety (BLS) Certification Maintenance (CM) point. continent, and makes our Laser and Intense Pulsed Light Physics and Safety Core of Knowledge course one of the most recognised globally.

Safety 78

Safety Training Education 78

Online Laser Training

AUGUST 13, 2020

version of our Laser/IPL Physics and Safety ‘Core of Knowledge’ course has been awarded 1 Board of Laser Safety (BLS) Certification Maintenance (CM) point. continent, and makes our Laser/IPL Physics and Safety ‘Core of Knowledge’ course one of the most recognised globally.

Safety 78

Safety Training Education 78

MedEsthetics

OCTOBER 30, 2023

The FDA recommends against the use of soft tissue fillers to increase breast size and the use of permanent fillers like silicone for cosmetic treatment, among other new guidelines.

Safety 148

Safety Treatments Injections 148

Dermatology Times

APRIL 5, 2024

Alexandra Golant, MD, explains why she is confident in the latest safety and efficacy data from ruxolitinib trials to treat pediatric patients with atopic dermatitis.

Safety 36

Safety Dermatitis 36

Dermatology Times

NOVEMBER 2, 2023

The results from this 5-year open-label extension trial affirm the safety of dupilumab in adults with moderate to severe AD.

Safety 75

Safety Dermatitis 75

Dermatology Times

JANUARY 9, 2024

Experts in dermatology emphasize the need to consider patients' overall well-being when evaluating the safety profiles of emerging biologic treatments for plaque psoriasis, taking into account the heightened levels of depression and anxiety in individuals with this condition.

Safety 36

Safety Treatments Dermatology 36

MedEsthetics

OCTOBER 30, 2023

Following a patient's death at Luxe Med Spa, the Texas Medical Board has declared that the spa's medical director Michael Gallagher, M.D. is a continuing threat to public welfare due to the doctor's improper supervision of IV treatments.

Med Spa 148

Med Spa Safety Therapy Medical 148

Professional Program Insurance Brokerage

SEPTEMBER 7, 2021

As a tattoo artist or tattoo studio owner, you know that safety and professionalism are essential. Our tattoo shop insurance specialists hear that it can be hard to make sure your staff is as safety conscious as you are. Here are some ideas for ensuring that everyone is following safety precautions and taking them seriously.

Safety 40

Safety Training 40

The Eco Well Podcasts

NOVEMBER 30, 2022

Topic: How is misinformation in the beauty world impacting cosmetics product safety, and how can we start to course correct? Is 'clean' beauty actually making cosmetics safer? This was the closing panel of our latest e-conference, the 'Safe' Beauty E-Summit. Panelists included Michelle Wong Ph.D.

Safety 52

Safety Cosmetic Products 52

The Dermatology Digest

JANUARY 15, 2024

In one study, researchers reported significant improvements in both clinician-assessed (IGA-CHE treatment success, HECSI) and patient-reported (DLQI) efficacy outcomes compared to cream vehicle, What’s more, delgocitinib cream 20 mg/g was well-tolerated over 16 weeks, and no safety concerns were identified.

Safety 36

Safety Eczema Dermatology Treatments 36

Dermatology Times

FEBRUARY 19, 2024

Katherine Economy, MD, discusses the challenges and opportunities of treating pregnant patients with dermatologic conditions, emphasizing the importance of comprehensive medication reviews, patient-centered decision-making, and the need for including pregnant patients in clinical trials.

Safety 69

Safety Dermatology Clinic Medical 69

The Dermatology Digest

DECEMBER 15, 2023

The comprehensive safety analysis establishes evidence regarding the safety of systematic Janus kinase inhibitors in patients with atopic dermatitis. They reviewed the available safety data and analyzed the risk of 11 adverse events from 14 RCTs published between 2019 and 2022.

Safety 36

Safety Dermatitis Dermatology Management 36

Texas Dermatology

OCTOBER 20, 2023

However, it’s crucial to prioritize safety when applying makeup to your skin. In this blog, we’ll discuss Halloween makeup safety tips, what to do if you encounter a bad skin reaction, and why scheduling a dermatology appointment at Texas Dermatology is essential for addressing skin issues.

Makeup 36

Makeup Safety Skin Issues Skincare Routine 36

The Dermatology Digest

JANUARY 21, 2024

What’s more, delgocitinib cream 20 mg/g was well-tolerated over 16 weeks, and no safety concerns were identified. JAK inhibitors are available orally, but given some safety concerns or contraindications, not all patients are suitable,” Dr. Gooderham says. laboratory parameter changes or safety concerns with twice daily application. “

Safety 36

Safety Eczema Social Media Dermatology 36

Dermatology Times

SEPTEMBER 6, 2023

Laura Bush, DMSc, PA-C, and Terry Faleye, MPAS, PA-C, reviews the safety data of TYK2 inhibitors compared to other systemic agents in the same class.

Safety 36

Safety Treatments 36

Dermatology Times

AUGUST 23, 2023

Lakshi Aldredge, MSN, ANP-BC, comments on the implications of long-term safety data in patients who may not have responded to initial treatment of plaque psoriasis.

Safety 36

Safety Treatments 36

Dermatology Times

AUGUST 24, 2023

Experts discuss the results of a study comparing the safety of Janus Kinase (JAK) inhibitors and systemic immunosuppressants in the treatment of atopic dermatitis (AD).

Safety 36

Safety Dermatitis Treatments 36

The Dermatology Digest

DECEMBER 15, 2023

They reviewed the available safety data and analyzed the risk of 11 adverse events from 14 RCTs published between 2019 and 2022. The post Review Study Aims to Refine Safety Profile of JAK Inhibitors in AD appeared first on The Dermatology Digest.

Safety 36

Safety Dermatitis Dermatology Management 36

Dermatology Times

AUGUST 16, 2023

Christopher Bunick, MD, PhD, introduces the objectives and design of a study comparing the safety of Janus Kinase (JAK) inhibitors and systemic immunosuppressants in the treatment of atopic dermatitis (AD).

Safety 36

Safety Dermatitis Treatments 36

MedEsthetics

JANUARY 8, 2024

The petition was filed on behalf of Public Citizen, a nonprofit consumer advocacy organization, and builds on a 2008 Public Citizen petition that asked the FDA to require the addition of the black-box warning on the labeling of Botox and related drugs.

Safety 78

Safety Injections 78

Dermatology Times

AUGUST 25, 2023

Christopher Bunick, MD, PhD, discusses a novel tool to visualize key safety results of Janus kinase inhibitors in treating patients with atopic dermatitis.

Safety 36

Safety Dermatitis Tools 36

Dermatology Times

FEBRUARY 2, 2024

Compared with cartridge razors, safety razors demonstrated a lower incidence of erythema.

Safety 36

Safety 36

Dermatology Times

NOVEMBER 12, 2023

Late-breaking data adds important safety and efficacy data for leukotriene receptor antagonists augmentation in chronic urticaria treatment.

Safety 36

Safety Treatments 36

Dermatology Times

AUGUST 9, 2023

Christopher Bunick, MD, PhD, discusses the major study conclusions about the safety of upadacitinib as a treatment for atopic dermatitis.

Safety 36

Safety Dermatitis Treatments 36

Dermatology Times

SEPTEMBER 25, 2023

Lilia Correa-Selm, MD, FAAD, FACMS, reviews the clinical trial data relating to the EVRIANCE study examining the use of vismodegib treatment in patients with locally advanced basal cell carcinoma, highlighting key efficacy and safety endpoints.

Safety 36

Safety Clinic Treatments 36

Dermatology Times

JANUARY 9, 2024

Experts in dermatology highlight the crucial role of setting treatment response expectations and stress the need for discussions on managing mild plaque psoriasis, highlighting the utilization of systemic therapies in this context.

Safety 69

Safety Education Therapy Management 69

Dermatology Times

MAY 13, 2024

They are confident prescribing roflumilast to patients with diverse skin and hair characteristics, including those with a history of hair treatments.

Safety 70

Safety Dermatitis Treatments 70

Dermatology Times

MAY 6, 2024

Elizabeth Kiracofe, MD, provides a look at an upcoming DermView program that will explore systemic treatments for atopic dermatitis in the context of reproductive health, for patients during pregnancy, pre-pregnancy, postpartum, and breastfeeding.

Dermatitis 36

Dermatitis Safety Treatments 36

Dermatology Times

DECEMBER 21, 2023

Dr Derm has recently been sued by a patient for simply asking the question “Do you own a gun?” He seeks legal advice.

Legal 66

Legal Safety 66

Dermatology Times

APRIL 19, 2024

Researchers examined local skin reactions of a topical gel inhibiting cytosolic phospholipase A2 both in-clinic and remotely.

Technology 79

Technology Safety Clinic 79

Dermatology Times

DECEMBER 11, 2023

Christopher Bunick, MD, PhD, presented the research during a late-breaking research session during the 2023 Revolutionizing Atopic Dermatitis Virtual Conference.

Safety 73

Safety Management Dermatitis 73

Les Nouvelles Esthetics & Spa

FEBRUARY 29, 2024

Inclusivity and client safety are key in the design of these systems. Ensuring that practices are accessible to all clients, regardless of background, and that safety protocols are rigorously maintained, is essential. For aesthetic practitioners, the administrative workload has always been a significant part of their daily routine.

Innovations 78

Innovations Management Client Safety Client Care 78

Dermatology Times

MARCH 28, 2024

Drs Mark Lebwohl and Saakshi Khattri review the significance of long-term data of bimekizumab for plaque psoriasis management.

Safety 36

Safety Management 36